
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1033 | 962 | 1033 | 1037 | 1249 | 1751 |
Fund Return | 3.29% | -3.78% | 3.29% | 1.21% | 4.55% | 5.76% |
Place in category | 1701 | 1360 | 1701 | 1236 | 1042 | 492 |
% in Category | 85 | 65 | 85 | 70 | 69 | 51 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Acatis Gane Value Event Fonds UI A | 6.41B | 2.83 | 6.07 | 6.37 | ||
Acatis Gane Value Event Fonds UI B | 6.41B | 2.89 | 6.51 | 6.82 | ||
Acatis Gane Value Event Fonds UI C | 6.41B | 2.83 | 6.06 | 6.23 | ||
ACATIS Datini Valueflex Fonds A | 699.09M | -1.78 | 2.04 | 10.73 | ||
ACATIS Datini Valueflex Fonds B | 699.09M | -1.93 | 1.18 | 9.90 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Wellington Strategic European EquiD | 4.02B | 17.60 | 10.31 | 9.12 | ||
Wellington Strategic European EquNE | 4.02B | 18.40 | 11.15 | 9.95 | ||
Wellington Strategic European EquiS | 4.02B | 18.57 | 11.31 | 10.10 | ||
AriDeka CF | 2.89B | 7.47 | 2.81 | 5.49 | ||
Industria P EUR | 1.52B | 7.58 | 6.75 | 5.90 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 5.04 | 463.4 | -0.70% | |
HSBC | GB0005405286 | 3.82 | 838.00 | -5.10% | |
Deutsche Telekom AG | DE0005557508 | 3.63 | 34.140 | +0.38% | |
ASML Holding | NL0010273215 | 3.61 | 593.50 | -3.70% | |
Compass | GB00BD6K4575 | 3.52 | 2,563.00 | -1.35% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Buy |
Technical Indicators | Strong Sell | Neutral | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review